Tags |
|
|
Links |
|
|
Top Articles - A Stuttered Sprint Into 2007
Open up your wallets, a new year of investing has officially begun. Stocks opened markedly higher in the first session of 2007 as investors cheered news that Home Depo
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
t Inc’s CEO resigned after years of lackluster performance, and that the holiday shopping season had been stronger than expected.
On Wednesday the DOW Jones touched a
On Wednesday the DOW Jones touched a
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
all-time intra-day high of 12,580.35. Stocks finished the day mixed after the latest Federal Reserve minutes showed worries about inflation and the scale of the housi
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
g sector pullback.
Fortunately, the Fed’s minutes date from December 12. Unfortunately, investors were looking for some fresh news, and instead the release of the min
Fortunately, the Fed’s minutes date from December 12. Unfortunately, investors were looking for some fresh news, and instead the release of the min
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
tes sapped strength from the market on a day that had seen triple digit gains.
For the most part, investors of every ilk are pretty bullish about 2007. Unlike last ye
For the most part, investors of every ilk are pretty bullish about 2007. Unlike last ye
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
r, when fears over global imbalances, energy costs and rising inflation made most commentators sound a note of caution, this year, most seem to be surprised that we ma
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
e it through 2006 intact – and see no reason why the current bull market shouldn’t continue.
One Wall Street economist said Wednesday’s pullback was overblown given r
One Wall Street economist said Wednesday’s pullback was overblown given r
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
cent data.
“It doesn’t make a lot of sense to react to something that is three weeks old and doesn’t incorporate the data that we got between now and then. The manufa
“It doesn’t make a lot of sense to react to something that is three weeks old and doesn’t incorporate the data that we got between now and then. The manufa
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
turing data today suggests things were OK as we headed into the end of the year,” he said.
Which makes total sense. Even though most economic forecasters are quick to
Which makes total sense. Even though most economic forecasters are quick to
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
point out that ‘past performance is no clear indicator of future performance’ (Dr. Phil of course states the opposite – who does one believe?), they almost all rely ex
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
lusively on very recent history to inform their opinions of what’s likely to happen in the coming year.
And what does our most recent economic history tell us? It tel
And what does our most recent economic history tell us? It tel
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ls us that 2007 will be a good year for small-cap and penny stocks. Domestically, small caps beat large caps, with the S&P Small Cap 600 advancing 15.1%; the Penny Sto
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
k Index advanced 9.3% since August (when the Index first began monitoring penny stocks).
Said another economic strategist, “The 1990s belonged to the large-caps, this
Said another economic strategist, “The 1990s belonged to the large-caps, this
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
decade, thus far, belongs to smaller companies,”
Still, even if large caps do outperform their penny stock peers, that doesn’t mean penny stocks will not have an exce
Still, even if large caps do outperform their penny stock peers, that doesn’t mean penny stocks will not have an exce
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
tionally strong year. Large cap gains do not sap strength on the backs of penny stocks.
If anything, blue-chip optimism often means investors are more willing to inve
If anything, blue-chip optimism often means investors are more willing to inve
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
t in smaller, riskier stocks. Which isn’t a bad idea, small caps stocks defied the experts once again in 2006 and outperformed their large cap peers; for the seventh y
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ar in a row.
So while I cannot - with Magic 8-Ball certainty – predict the markets in 2007, I think things look good for penny stock investors. The current bull marke
So while I cannot - with Magic 8-Ball certainty – predict the markets in 2007, I think things look good for penny stock investors. The current bull marke
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
has entered its 6th year and there’s no reason to think it will not continue.
As one economic advisor noted, despite going through a mid-cycle slowdown, there is no
As one economic advisor noted, despite going through a mid-cycle slowdown, there is no
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
eason to think we are heading into a recession. With interest rates and gas prices stable, consumers should continue to spend and send the economy higher.
While many
While many
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
conomists think U.S. blue chips will see returns of about 8%, our recent history shows us that penny stocks should, once again, outshine their mid and larger-cap peers
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/102072/toparticles-A-Stuttered-Sprint-Into-2007.html">A Stuttered Sprint Into 2007</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/102072/toparticles-A-Stuttered-Sprint-Into-2007.html]A Stuttered Sprint Into 2007[/url]
Related Articles:
Making Money With Your Crafty Creations
Search Engine Optimization-All You Need to Know About On-Page Optimization
Bookmark it:
|